Department of Trauma-, Hand- and Reconstructive Surgery, University Hospital, Erlanger Allee 101, 07740 Jena, Germany.
Am J Sports Med. 2011 Feb;39(2):311-9. doi: 10.1177/0363546510381575. Epub 2010 Nov 10.
Conventional autologous chondrocyte transplantation in the ankle often requires tibial or fibular osteotomies with potential morbidity for the patient. Advances in biotechnology and surgical techniques have resulted in the development of matrix-associated chondrocyte implantation (MACI). As the chondrocyte-loaded scaffold can be applied arthroscopically, this procedure is especially useful for the treatment of osteochondral defects in the ankle.
Arthroscopic MACI is a safe procedure in the ankle with good clinical and magnetic resonance imaging results.
Case series; Level of evidence, 4.
The authors reviewed all patients (n = 18) who had arthroscopic MACI for osteochondral lesions of the ankle (n = 19) between February 2006 and May 2008 clinically and with magnetic resonance imaging. The pain and disability module of the Foot Function Index (FFI), the American Orthopaedic Foot & Ankle Society (AOFAS) clinical rating system, the Core Scale of the Foot and Ankle Module of the American Academy of Orthopaedic Surgeons (AAOS) Lower Limb Outcomes Assessment Instruments, and the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score were used. The clinical results up to 3 years after MACI (mean follow-up, 24.5 months) were compared with preoperative data for 14 cases and the magnetic resonance imaging data for all 19.
A significant improvement (50.3% ± 13.2%) in all clinical scores was noted (FFI pain before MACI: 5.5 ± 2.0, after MACI: 2.8 ± 2.2; FFI disability before MACI: 5.0 ± 2.3, after MACI: 2.6 ± 2.2; AOFAS before MACI: 58.6 ± 16.1, after MACI: 80.4 ± 14.1; AAOS standardized mean before MACI: 59.9 ± 16.0, after MACI: 83.5 ± 13.2; AAOS normative score before MACI: 23.0 ± 13.0, after MACI: 42.2 ± 10.7). According to the AOFAS Hindfoot score, 64% were rated as excellent and good, whereas 36% were rated fair and poor. The results correlated with the age of the patient and the duration of symptoms, but not with the size of the lesion. Sixteen patients (89%) reported regular sports activities before the onset of symptoms; 13 of them (81%) returned to sports after the MACI, 56% (n = 9) to the same level. The mean MOCART score was 62.4 ± 15.8 points. In general, there was no relation between MOCART score and clinical outcome, although the filling of the defect showed some correlation with the AAOS score.
Arthroscopic MACI is a safe procedure for the treatment of osteochondral lesions in the ankle with overall good clinical and magnetic resonance imaging results.
踝关节常规的自体软骨细胞移植通常需要胫骨或腓骨切开术,这会给患者带来潜在的发病率。生物技术和外科技术的进步带来了基质相关软骨细胞植入(MACI)的发展。由于负载软骨细胞的支架可以通过关节镜应用,因此该手术特别适用于治疗踝关节的骨软骨缺损。
关节镜 MACI 是一种安全的踝关节手术,具有良好的临床和磁共振成像结果。
病例系列;证据水平,4 级。
作者回顾了 2006 年 2 月至 2008 年 5 月期间接受关节镜 MACI 治疗踝关节骨软骨病变的所有患者(n = 19)的临床和磁共振成像资料。使用足部功能指数(FFI)的疼痛和残疾模块、美国矫形足踝协会(AOFAS)临床评分系统、矫形外科医师学会足部和踝关节模块的核心量表(AAOS)下肢结局评估工具以及磁共振软骨修复组织观察(MOCART)评分。将 MACI 后 3 年的临床结果(平均随访,24.5 个月)与 14 例术前数据和所有 19 例磁共振成像数据进行比较。
所有临床评分均有显著改善(50.3%±13.2%)(FFI 术前疼痛:5.5±2.0,术后:2.8±2.2;FFI 术前残疾:5.0±2.3,术后:2.6±2.2;AOFAS 术前:58.6±16.1,术后:80.4±14.1;AAOS 标准化平均术前:59.9±16.0,术后:83.5±13.2;AAOS 标准评分术前:23.0±13.0,术后:42.2±10.7)。根据 AOFAS 后足评分,64%被评为优秀和良好,36%评为一般和差。结果与患者年龄和症状持续时间相关,但与病变大小无关。16 名患者(89%)报告在症状发作前有规律的体育活动;其中 13 名(81%)在 MACI 后恢复运动,56%(n=9)恢复到相同水平。平均 MOCART 评分为 62.4±15.8 分。一般来说,MOCART 评分与临床结果之间没有关系,尽管缺损的填充与 AAOS 评分有一定的相关性。
关节镜 MACI 是治疗踝关节骨软骨病变的一种安全手术,具有整体良好的临床和磁共振成像结果。